NATb/NAT1 4 promotes greater arylamine N-acetyltransferase 1 mediated DNA adducts and mutations than NATa/NAT1 4 following exposure to 4-aminobiphenyl

Molecular Carcinogenesis

Volumn 51, Issue 8, 2012, Pages 636-646

  Millner, Lori M ^a   Doll, Mark A ^a   Cai, Jian ^a   States, J Christopher ^a   Hein, David W ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

4 aminobiphenyl; Alternative mRNA isoforms; Arylamine DNA adducts; Hprt mutants; N acetyltransferase 1

Indexed keywords

4 BIPHENYLAMINE; ARYLAMINE ACETYLTRANSFERASE; ARYLAMINE ACETYLTRANSFERASE 1; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MESSENGER RNA; UNCLASSIFIED DRUG; 4-BIPHENYLAMINE; AMINOBIPHENYL DERIVATIVE; CARCINOGEN; ISOENZYME;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA ADDUCT; DNA POLYMORPHISM; ENZYME ACTIVITY; EXCISION REPAIR; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; IN VITRO STUDY; KIDNEY FUNCTION; LIVER FUNCTION; LUNG FUNCTION; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TRACHEA; TRANSCRIPTION REGULATION; ACETYLATION; ALTERNATIVE RNA SPLICING; ANIMAL; BIOTRANSFORMATION; CELL STRAIN COS1; CELL STRAIN HEPG2; CELL SURVIVAL; CERCOPITHECUS; CHO CELL; CRICETULUS; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HAMSTER; METABOLISM; MUTATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

CRICETULUS GRISEUS;

5' UNTRANSLATED REGIONS; ACETYLATION; ALTERNATIVE SPLICING; AMINOBIPHENYL COMPOUNDS; ANIMALS; ARYLAMINE N-ACETYLTRANSFERASE; BIOTRANSFORMATION; BLOTTING, WESTERN; CARCINOGENS; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; CHO CELLS; COS CELLS; CRICETINAE; CRICETULUS; DNA ADDUCTS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEP G2 CELLS; HUMANS; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; ISOENZYMES; MUTATION; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84863562750     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20836     Document Type: Article

References (51)

1. International Agency for Research on Cancer. Overall evaluation of carcinogenicity: An update of IARC monographs, Supplement 7, Vols. 1-42. Monographs on the evaluation of carcinogenic risk to humans; 1987.
2. Hein DW, Doll MA, Rustan TD, et al. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 1993; 14: 1633-1638.
3. Wakefield L, Cornish V, Long H, Griffiths WJ, Sim E. Deletion of a xenobiotic metabolizing gene in mice affects folate metabolism. Biochem Biophys Res Commun 2007; 364: 556-560.
4. Jensen LE, Hoess K, Whitehead AS, Mitchell LE. The NAT1 C1095A polymorphism, maternal multivitamin use and smoking, and the risk of spina bifida. Birth Defects Res A Clin Mol Teratol 2005; 73: 512-516.
5. Lammer EJ, Shaw GM, Iovannisci DM, Van Waes J, Finnell RH. Maternal smoking and the risk of orofacial clefts: Susceptibility with NAT1 and NAT2 polymorphisms. Epidemiology 2004; 15: 150-156.
6. Carmichael SL, Shaw GM, Yang W, Iovannisci DM, Lammer E. Risk of limb deficiency defects associated with NAT1, NAT2, GSTT1, GSTM1, and NOS3 genetic variants, maternal smoking, and vitamin supplement intake. Am J Med Genet A 2006; 140: 1915-1922.
7. Jensen LE, Hoess K, Mitchell LE, Whitehead AS. Loss of function polymorphisms in NAT1 protect against spina bifida. Hum Genet 2006; 120: 52-57.
8. Millikan RC, Pittman GS, Newman B, et al. Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998; 7: 371-378.
9. Zheng W, Deitz AC, Campbell DR, et al. N-acetyltransferase 1 genetic polymorphism, cigarette smoking, well-done meat intake, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999; 8: 233-239.
10. Li D, Jiao L, Li Y, et al. Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis 2006; 27: 103-111.
11. Suzuki H, Morris JS, Li Y, et al. Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer. Carcinogenesis 2008; 29: 1184-1191.
12. Sanderson S, Salanti G, Higgins J. Joint effects of the N-acetyltransferase 1 and 2 (NAT1 and NAT2) genes and smoking on bladder carcinogenesis: A literature-based systematic HuGE review and evidence synthesis. Am J Epidemiol 2007; 166: 741-751.
13. Gago-Dominguez M, Bell DA, Watson MA, et al. Permanent hair dyes and bladder cancer: Risk modification by cytochrome P4501A2 and N-acetyltransferases 1 and 2. Carcinogenesis 2003; 24: 483-489.
14. Shin A, Shrubsole MJ, Rice JM, et al. Meat intake, heterocyclic amine exposure, and metabolizing enzyme polymorphisms in relation to colorectal polyp risk. Cancer Epidemiol Biomarkers Prev 2008; 17: 320-329.
15. Bell DA, Stephens EA, Castranio T, et al. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res 1995; 55: 3537-3542.
16. Morton LM, Schenk M, Hein DW, et al. Genetic variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2) and risk of non-Hodgkin lymphoma. Pharmacogenet Genomics 2006; 16: 537-545.
17. Kilfoy BA, Zheng T, Lan Q, et al. Genetic variation in N-acetyltransferases 1 and 2, cigarette smoking, and risk of non-Hodgkin lymphoma. Cancer Causes Control 2010; 21: 127-133.
18. Adam PJ, Berry J, Loader JA, et al. Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Mol Cancer Res 2003; 1: 826-835.
19. Ring BZ, Seitz RS, Beck R, et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3039-3047.
20. McGrath M, Michaud D, De Vivo I. Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2 genes and bladder cancer risk in men and women. BMC Cancer 2006; 6: 239.
21. Wideroff L, Vaughan TL, Farin FM, et al. GST, NAT1, CYP1A1 polymorphisms and risk of esophageal and gastric adenocarcinomas. Cancer Detect Prev 2007; 31: 233-236.
22. Kidd LR, Hein DW, Woodson K, et al. Lack of association of the N-acetyltransferase NAT1*10 allele with prostate cancer incidence, grade, or stage among smokers in Finland. Biochem Genet 2011; 49: 73-82.
23. Tiang JM, Butcher NJ, Cullinane C, Humbert PO, Minchin RF. RNAi-mediated knock-down of arylamine N-acetyltransferase-1 expression induces e-cadherin up-regulation and cell-cell contact growth inhibition. PLoS ONE 2011; 6: e17031.
24. Vatsis KP, Weber WW. Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Arch Biochem Biophys 1993; 301: 71-76.
25. Boukouvala S, Sim E. Structural analysis of the genes for human arylamine N-acetyltransferases and characterisation of alternative transcripts. Basic Clin Pharmacol Toxicol 2005; 96: 343-351.
26. Husain A, Barker DF, States JC, Doll MA, Hein DW. Identification of the major promoter and non-coding exons of the human arylamine N-acetyltransferase 1 gene (NAT1). Pharmacogenetics 2004; 14: 397-406.
27. Barker DF, Husain A, Neale JR, et al. Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1. Pharmacogenet Genomics 2006; 16: 515-525.
28. Minchin RF, Hanna PE, Dupret JM, Wagner CR, Rodrigues-Lima F, Butcher NJ. Arylamine N-acetyltransferase I. Int J Biochem Cell Biol 2007; 39: 1999-2005.
29. Nechaev S, Fargo DC, dos Santos G, Liu L, Gao Y, Adelman K. Global analysis of short RNAs reveals widespread promoter-proximal stalling and arrest of Pol II in Drosophila. Science 2010; 327: 335-338.
30. Aida M, Chen Y, Nakajima K, Yamaguchi Y, Wada T, Handa H. Transcriptional pausing caused by NELF plays a dual role in regulating immediate-early expression of the junB gene. Mol Cell Biol 2006; 26: 6094-6104.
31. Takeda J, Suzuki Y, Nakao M, et al. H-DBAS: Alternative splicing database of completely sequenced and manually annotated full-length cDNAs based on H-Invitational. Nucleic Acids Res 2007; 35: D104-D109.
32. Cooper SJ, Trinklein ND, Anton ED, Nguyen L, Myers RM. Comprehensive analysis of transcriptional promoter structure and function in 1% of the human genome. Genome Res 2006; 16: 1-10.
33. Horton RM, Hunt HD, Ho SN, Pullen JK, Pease LR. Engineering hybrid genes without the use of restriction enzymes: Gene splicing by overlap extension. Gene 1989; 77: 61-68.
34. Metry KJ, Zhao S, Neale JR, et al. 2-Amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine-induced DNA adducts and genotoxicity in chinese hamster ovary (CHO) cells expressing human CYP1A2 and rapid or slow acetylator N-acetyltransferase 2. Mol Carcinog 2007; 46: 553-563.
35. Hein DW, Doll MA, Nerland DE, Fretland AJ. Tissue distribution of N-acetyltransferase 1 and 2 catalyzing the N-acetylation of 4-aminobiphenyl and O-acetylation of N-hydroxy-4-aminobiphenyl in the congenic rapid and slow acetylator Syrian hamster. Mol Carcinog 2006; 45: 230-238.
36. Stanley LA, Coroneos E, Cuff R, Hickman D, Ward A, Sim E. Immunochemical detection of arylamine N-acetyltransferase in normal and neoplastic bladder. J Histochem Cytochem 1996; 44: 1059-1067.
37. Wu RW, Tucker JD, Sorensen KJ, Thompson LH, Felton JS. Differential effect of acetyltransferase expression on the genotoxicity of heterocyclic amines in CHO cells. Mutat Res 1997; 390: 93-103.
38. Husain A, Zhang X, Doll MA, States JC, Barker DF, Hein DW. Functional analysis of the human N-acetyltransferase 1 major promoter: Quantitation of tissue expression and identification of critical sequence elements. Drug Metab Dispos 2007; 35: 1649-1656.
39. Wakefield L, Robinson J, Long H, et al. Arylamine N-acetyltransferase 1 expression in breast cancer cell lines: A potential marker in estrogen receptor-positive tumors. Genes Chromosomes Cancer 2008; 47: 118-126.
40. Butcher NJ, Arulpragasam A, Goh HL, Davey T, Minchin RF. Genomic organization of human arylamine N-acetyltransferase Type I reveals alternative promoters that generate different 5′-UTR splice variants with altered translational activities. Biochem J 2005; 387: 119-127.
41. Davuluri RV, Suzuki Y, Sugano S, Plass C, Huang TH. The functional consequences of alternative promoter use in mammalian genomes. Trends Genet 2008; 24: 167-177.
42. Core LJ, Waterfall JJ, Lis JT. Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters. Science 2008; 322: 1845-1848.
43. Adelman K, La Porta A, Santangelo TJ, Lis JT, Roberts JW, Wang MD. Single molecule analysis of RNA polymerase elongation reveals uniform kinetic behavior. Proc Natl Acad Sci USA 2002; 99: 13538-13543.
44. Herbert KM, La Porta A, Wong BJ, et al. Sequence-resolved detection of pausing by single RNA polymerase molecules. Cell 2006; 125: 1083-1094.
45. Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-355.
46. Doench JG, Sharp PA. Specificity of microRNA target selection in translational repression. Genes Dev 2004; 18: 504-511.
47. Zhang H, Kolb FA, Jaskiewicz L, Westhof E, Filipowicz W. Single processing center models for human Dicer and bacterial RNase III. Cell 2004; 118: 57-68.
48. Calvo SE, Pagliarini DJ, Mootha VK. Upstream open reading frames cause widespread reduction of protein expression and are polymorphic among humans. Proc Natl Acad Sci USA 2009; 106: 7507-7512.
49. Malys N, McCarthy JE. Translation initiation: Variations in the mechanism can be anticipated. Cell Mol Life Sci 2011; 68: 991-1003.
50. Larson DR, Zenklusen D, Wu B, Chao JA, Singer RH. Real-time observation of transcription initiation and elongation on an endogenous yeast gene. Science 2011; 332: 475-478.
51. Bendaly J, Doll MA, Millner LM, et al. Differences between human slow N-acetyltransferase 2 alleles in levels of 4-aminobiphenyl-induced DNA adducts and mutations. Mutat Res 2009; 671: 13-19.